Navin Jacob
Stock Analyst at UBS
(2.83)
# 1,542
Out of 4,829 analysts
27
Total ratings
64.29%
Success rate
18.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Navin Jacob
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Neutral | $181 → $190 | $184.60 | +2.93% | 13 | Feb 3, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $363 | $734.57 | -50.58% | 8 | Sep 22, 2022 | |
| RPRX Royalty Pharma | Upgrades: Buy | $51 | $33.15 | +53.85% | 1 | Nov 9, 2020 | |
| GILD Gilead Sciences | Downgrades: Neutral | n/a | $96.91 | - | 1 | Apr 27, 2020 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $92 | $75.97 | +21.10% | 4 | Apr 13, 2020 |
AbbVie
Feb 3, 2025
Maintains: Neutral
Price Target: $181 → $190
Current: $184.60
Upside: +2.93%
Eli Lilly and Company
Sep 22, 2022
Upgrades: Buy
Price Target: $363
Current: $734.57
Upside: -50.58%
Royalty Pharma
Nov 9, 2020
Upgrades: Buy
Price Target: $51
Current: $33.15
Upside: +53.85%
Gilead Sciences
Apr 27, 2020
Downgrades: Neutral
Price Target: n/a
Current: $96.91
Upside: -
Merck & Co.
Apr 13, 2020
Maintains: Buy
Price Target: $96 → $92
Current: $75.97
Upside: +21.10%